Argenx to buy peptide platform in potentially billion-dollar deal

AI Summary

Argenx has agreed to acquire Unnatural Products’ macrocyclic peptide platform for $550 million upfront, with the total value potentially reaching $1 billion. Argenx plans to use the technology to develop oral, longer-lasting medicines for serious immune-mediated diseases.

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.